Loading...
11 12 18
21:01 PM

  $89.69

Sector
Manufacturing COMPARE IN SECTOR
Industry
PHARMACEUTICAL PREPARATIONS COMPARE IN INDUSTRY
Company Info - Overview CLICK HERE TO GET INFO

Valuation

Market Capitalization (D) 135.88B
Trailing P/E (D) 18.57
Price / Sales (D) 4.22
Price / Book (D) -46.52
Book Value Per Share (Q) -1.93
Basic EPS (Q) 1.82
Diluted EPS (Q) 1.81
Ex-Date (Q) 10/12/2018
Dividend Per Share (Q) 0.96
Annual Yield (D) 4.00%

RANKING PERFORMANCE LAST 30 DAYS


30-DAY STOCK PERFORMANCE RANKING (out of 6113 companies)


0-30 DAYS 30-60 DAYS 60-90 DAYS 90-120 DAYS 120-150 DAYS 150-180 DAYS
N/A N/A N/A N/A N/A N/A
180-210 DAYS 210-240 DAYS 240-270 DAYS 270-300 DAYS 300-330 DAYS 330-360 DAYS
N/A N/A N/A N/A N/A N/A

Company Description

AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson's disease; complications associated with chronic kidney disease and cystic fibrosis; and other health conditions such as low testosterone. AbbVie also has a pipeline of promising new medicines, including more than 30 compounds or indications in Phase 2 or Phase 3 development across such important medical specialties as immunology, virology/liver disease, oncology, renal disease, neurological diseases and women's health.

Range: 3m 6m 1y 2y max

No Chart Information

Profitability  

Gross Margin (TTM) 75.22%    0.29%
Net Profit Margin (TTM) 23.50%    2.66%

Efficiency  

Return on Assets (TTM) 11.43%    0.97%
Return on Equity (TTM) -258.99%    67.91%

Liquidity  

Current Ratio (Q) 1.20    49.29%
Quick Ratio (Q) 0.95    70.97%

Capital Structure  

Debt:Equity (Q) -23.65    22.77%
Debt:Asset (Q) 1.04    1%

Miscellaneous  

Basic Average Shares Outstanding (Q) 1.51B    3.64%
Fully Diluted Average Shares Outstanding (Q) 1.52B    3.63%